



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

15 January 2018
EMA/INS/GMP/35037/2017
Committees and Inspections
Manufacturing and Quality Compliance

How to use the defective product report to notify a quality defect to European Medicines Agency



Table of contents

1. The Defective Product Report (DPR)	3
2. Reporter details	3
3. Product details	4
4. Defect details	6
5. Investigation and action details	7
6. List of abbreviations	8
7. Annex – Defect categorisation terminology adopted	9

1. The Defective Product Report (DPR)

1.1 Download the DPR template on European Medicines Agency (EMA) [external website](#).

1.2 It is the responsibility of the reporter to ensure that information provided is accurate and complete.

1.3 Mandatory fields (**marked in red**) must to be completed in order to save and send the DPR.

1.4 The new DPR temple is divided into four parts:

- **Reporter Details**
- **Product Details**
- **Defect Details**
- **Investigation and actions details**

1.5 What follows is the description of the main features present in the new EMA report. Most of the fields are self-explanatory. If there are any data fields that are not clear do not hesitate to contact us at qdefect@ema.europa.eu

2. Reporter details

This section captures the details of the reporter.

Annex 1 to SOP EMA: SOP/INSP/2018

EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH		
Defective Product Report		
Medicine Type	Date/Time of Submission	
<input type="text"/>	<input type="text"/>	
1 REPORTER DETAILS		
Reporter	Company	Representing
<input type="text"/>	<input type="text"/>	<input type="text"/>
Address	E-mail	Direct Phone Number
<input type="text"/>	<input type="text"/>	<input type="text"/>

2.1 **Date/Time of Submission:** this field is automatically completed on clicking “Submit Notification”. The e-mail address (qdefects@ema.europa.eu) will automatically be inserted on the address bar of your e-mail.

2.2 **Medicine Type:** choose the correct selection from the dropdown menu (Human/Veterinary/both)

2.3 **Reporter, Company, Address, E-mail** and **Direct Phone Number** are all self-explanatory.

2.4 **Representing:** choose the correct selection from the dropdown menu:

- **Manufacturer**

- MAH (Marketing Authorisation Holder)
- Parallel Distributor/ Parallel Importer
- Wholesaler
- Other, please specify

If other, please detail in the related field.

Note that only reports from “Parallel Distributors” and related to Centrally Authorised Products (CAPs) are sent to the EMA. Reports related to Nationally Authorised Products (NAPs) and Mutual Recognition Procedure/ Decentralised Procedure (MRP/DCP) are required to be sent to the relevant National Competed Authority.

3. Product details

This section captures details of product (s) and batch (es) affected by the issue being reported.

2 PRODUCT DETAILS									
+ Product - Product									
1	Product	INN	MA Type	MA Number	Strength				
Pharmaceutical Form			Route of Administration		Presentation/packaging				
Manufacturer of the Batch			Site of Batch Release		Marketing Authorisation Holder				
Name		Name		Name					
Address		Address		Address					
+ Batch -Batch									
1.1	Batch Size	Units Affected	Batch N	Expiry Date	Manufacturing Date	Product Distribution	Pack	Language (s)	

3.1. All fields in this section are mandatory and self-explanatory.

3.2 Tables can be duplicated by clicking respectively on:

+ **Product**: this function duplicates the entire table and allows reporting of additional products impacted by the quality defect (QD). A sequential number (e.g. 1,2,3. Etc.) is assigned to each product/MA number impacted.

+ **Batch**: this function duplicates the batch table allowing the reporting of all batches of a particular product / MA number impacted by the QD. A sequential sub-number referring to the product reported will be assigned (e.g. for the first product reported (assigned product 1) batch numbers impacted will be linked as 1.1, 1.2 and 1.3; for product 2 impacted batches will be captured as 2.1, 2.2, 2.3 etc.).

3.3 **MA Type**: choose the correct selection from the dropdown menu (CAP/NAP/MRP/DCP).

Note that only reports related to CAPs are sent to EMA. Reports related to Nationally Authorised Products (NAPs) and Mutual Recognition Procedure/ Decentralised Procedure (MRP/DCP) are required to be sent to the relevant National Competed Authority.

3.4 **Presentation/packaging**: provide the number of units present in each pack, as per marketing authorisation (e.g. 2 blisters containing 15 tables each)

3.5 **Manufacturer of the Batch** and **Site of Batch Release** are fields to be completed.

4. Defect details

This section captures the description and categorisation of the defect identified.

3 DEFECT DETAILS	
Defect Description	
<input type="text"/>	
+ -	
Defect Category	Defect Descriptor
<input type="text"/>	<input type="text"/>
Site where the defect occurred	
Name	Address
<input type="text"/>	<input type="text"/>

4.1 All fields are mandatory. Free text boxes allow the reporter extra flexibility.

4.2 **Defect Description:** use free text to describe in detail the issue being reported.

4.3 **Defect Category:** choose the correct selection from the dropdown menu. This contains 5 High Level Terminology (HLTs) enabling the defect to be categorised.

4.4 **Defect Descriptor:** choose the correct selection from the dropdown menu. This contains a set of Preferred Terminology (PTs) linked to the HLT previously selected. Refer to Annex 1 for more details.

4.5 **Site where the defect occurred:** name and address of the facility where the defect originated.

5. Investigation and action details

This final part captures information on the investigation performed and the actions planned/proposed.

4 INVESTIGATION AND ACTION DETAILS	
Summary of the investigation	
Competent Authority (ies) Contacted	
Adverse Reactions/ Events and Reoccurrence Identified (report according to applicable pharmacovigilance requirements for human medicines or veterinary medicines .)	
Proposed Action	Justification of the Proposed Action
Proposed Depth of the Recall	Consequences of proposed action on market
-> In the event that the agreed action intended to take is leading to disruption in product supply, please verify if a Withdrawn Product Notification is needed.	
Description of the Root Cause Identified/Expected	Root Cause Details
<input type="button" value="+ CAPA"/> <input type="button" value="- CAPA"/>	
1 Proposed/Taken CAPA to Prevent Issue Reoccurrence	CAPA Implementation Timeline
! Please provide in timely fashion: investigation report including CAPAs, health hazard risk assessment report, photos, test results and any other documentation, if needed.	
<input type="button" value="Attach Files"/>	
Please attach the investigation and any other relevant documentation.	
<input type="button" value="Submit Notification"/>	

5.1 Summary of the investigation: summarise the main findings of the investigation. Provide the investigation report.

5.2 Proposed Action: choose the correct selection from the dropdown menu (Market Suspension/ No Recall/Quarantine/Recall Class I/Recall Class II/Recall Class III/Other, please specify). If other please detail in the related field. Note any action proposed must be agreed with the local authority.

5.3 Consequences of proposed action on market: evaluate the impact of the proposed action on the market. Inform the Agency in case product market disruption is foreseen. Verify if the foreseen consequence is such that a [Withdrawn Product Notification](#) is required.

5.4 Attach Files: Attach as a minimum investigation report, corrective actions/preventive actions (CAPAs) and health hazard risk assessment report. Add any relevant data to support the regulatory review of the case. If any information is outstanding at the time of the reporting provide a timeline for submission.

6. List of abbreviations

CAP: Centrally authorised product

CAPA: Corrective actions preventive action

DPR: Defective product report

EMA: European Medicines Agency

HLT: High Level Terminology

INN: International non proprietary name

NAP: nationally authorised product

MA: Marketing authorisation

MRP/DCP: mutual recognition procedure/ decentralised procedure

PT: Preferred Terminology

7. Annex – Defect categorisation terminology adopted

SOC System Organ Class	HLGT High Level Group Term	HLT High Level Term	PT Preferred Term	Examples	
Product issues	Product quality, supply, distribution, manufacturing and quality issues	*1.0 Manufacturing laboratory controls issue	1.1 Manufacturing laboratory controls issue	Process control issue/ Product quality control issue	
			1.2 Out of specification test results	Any type of OOS (stability, release for API and finished product) Product formulation issue Product impurity Product compounding issue Product measured potency issue Product quality issue (more details required)	
		2.0 Product contamination and sterility issues		2.1 Product contamination chemical	Pharmaceutical product contamination Preservation media contamination Therapeutic product contamination Product biofilm coating
				2.2 Product contamination microbial	Product contamination bacterial/ viral/ fungal/ endotoxin/ exotoxin
				2.3 Product contamination physical	Product contamination foreign material/ glass/ hair/ insect/ metal/ plastic/ soil Product contamination particulate matter
				2.4 Product contamination with body fluid	Product contamination with blood/ blood derivative
				2.5 Product sterility lacking	Product sterile packaging disrupted Product sterile packaging missing
				2.6 Suspected transmission of an infectious agent via product	
				3.0 Product label issues	
		3.2 Product barcode issue	Product barcode missing Product barcode on wrong product		

SOC System Organ Class	HLGT High Level Group Term	HLT High Level Term	PT Preferred Term	Examples
				Product barcode readability issue
			3.3 Product expiration date issue	Product expiration date illegible/ incorrect /missing
			3.4 Product identification number issue	Product identification number (excluding batch/lot) illegible/ incorrect /missing
			3.5 Product label issue	Carton label issue Product label issue
			3.6 Product label on wrong product	
			3.7 Product lot number issue	Product lot/ batch number illegible/ incorrect/ missing
		4.0 Product packaging issues	4.1 Product blister packaging issue	Product blister packaging separated Unit-dose blister pack issue
			4.2 Product closure issue	Product closure deterioration/ missing Product stopper coring
			4.3 Product commingling	Wrong and correct product strengths in same container Wrong and correct product in same container
			4.4 Product container issue	Product container damaged/ leak/ size or type incorrect
			4.5 Product container seal issue	
			4.6 Product dropper issue	Product dropper calibration unreadable/ improperly calibrated Product dropper missing/ tip issue/ tip missing
			4.7 Product outer packaging issue	
			4.8 Product packaging issue	
			4.9 Product packaging quantity issue	Package dosage units missing Package empty units Package quantity incorrect (overfilling-under filling) Unit-dose packaging partial fill

SOC System Organ Class	HLGT High Level Group Term	HLT High Level Term	PT Preferred Term	Examples
		5.0 Product physical issues	5.1 Product coating issue	Product coating cracked/ incomplete Ophthalmic medication precipitation
			5.2 Product deposit	Product crystals/deposit/precipitate/sedimentation present
			5.3 Product dosage form issue	Product dosage form imprint incorrect
			5.4 Product gel formation	
			5.5 Product physical issue	Product colour issues Product friable Product shape issue Product size issue Product solubility abnormal/decreased/increased Product reconstitution issue Product taste abnormal Product odour abnormal Product adhesion issue (e.g. medicinal patch adhesion issue) Product difficult to swallow/ Product too hard to chew Capsule extra shell/ fill abnormal/ separation issue Tablet chipped/ clumping/ cracked/ damaged issue
				Product leakage
				Product physical consistency issue

* Numbers for HLTs and PTs have been added by EMA for defect classification purposes.